Radionetics Oncology
Yunfei (Frank) Zhu is the Chief Research Officer at Radionetics Oncology. Prior to this role, Zhu was the Co-founder and Vice President, Chemistry at Crinetics Pharmaceuticals. With a background in medicinal chemistry, Zhu has played key roles in the discovery and development of novel treatments for various diseases targeting G-protein coupled receptors. Starting as a Senior Research Chemist at BioResearch, Zhu has worked his way up the ladder, earning promotions and contributing significantly to the pharmaceutical industry.
Radionetics Oncology
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.